32
total announcements
VIYASH.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹9,759 Cr
P/E (TTM)
54.1
P/E (Forward)
18.8
EPS (TTM)
₹4.09
52W Low
₹178.13
52W High
₹298.00
Dividend Yield
0.00%
Beta
0.98
Price / Book
3.3
Debt / Equity
15.7
Revenue (TTM)
₹3,575 Cr
Gross Margin
52.33%
Operating Margin
12.47%
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about change in Management, with Dr. Mallikharjuna Rao Nagineni appointed as Senior Vice President, Human Resources, and Mr. Prasad Lad ceasing to be a Senior Management Personnel due to his forthcoming retirement.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange regarding the allotment of 135,880 shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the allotment of ESOP (Employee Stock Option Plan) shares. The company has approved the allotment of 1,35,880 equity shares to eligible optionees under Sequent ESOP 2020 and Viyash ESOP 2026. The shares will rank pari passu with the existing equity shares and increase the issued and paid-up equity share capital of the company.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018. The company has enclosed a certificate issued in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, by KFin Technologies Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended September 30, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has completed the acquisition of 100% of the share capital of BioForLife Italia S.r.l. for EUR 15.0 million, with a deferred consideration of EUR 1.976 million.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the allotment of 11,07,309 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026.
Viyash Scientific Limited
Viyash Scientific Limited has received regulatory approval for the acquisition of 100% shareholding in BioForLife Italia S.r.l. and expects to complete the transaction within two months.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the allotment of 6,12,773 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026.
Viyash Scientific Limited
Viyash Scientific Limited has announced its Q1 FY'27 earnings, with revenue from operations growing 20% year-on-year to Rs. 946 crores, EBITDA increasing 59% to Rs. 205 crores, and profit after tax more than doubling to Rs. 79 crores. The company's balance sheet has improved, with net debt decreasing to Rs. 86 crores and net debt to EBITDA ratio reducing to 0.1x.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about the link of earnings call recording for the unaudited financial results (consolidated and standalone) for the quarter ended June 30, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has published a copy of newspaper publication for its Q1 FY 27 financial results, as per Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about Investor Presentation, enclosing the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The presentation highlights the company's continued success in integration efforts, robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing the strategic focus on the companion animal segment, providing market access and a platform to launch the product portfolio in key European markets.
Viyash Scientific Limited
Viyash Scientific Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 11, 2026. The company has informed the Exchange regarding voting results for all resolutions set out in the Notice dated May 19, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026.
Viyash Scientific Limited
Viyash Scientific Limited has announced its Q1 FY 2026-27 financial results, with revenues up 19.5% to ₹ 9,464 million, EBITDA up 59.2% to ₹ 2,047 million, and PAT up 114.9% to ₹ 793 million.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about General Updates Allotment of ESOP under Viyash Scientific Limited -Employee Stock Option Scheme 2026. The company has also approved the incorporation of a wholly owned subsidiary in Vietnam and investment therein, and subscription of equity shares in Alivira Animal Health Limited through Rights Issue.
Viyash Scientific Limited
Viyash Scientific Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with an independent auditor's limited review report. The company has also approved the allotment of equity shares to employees under the Viyash Scientific Limited Employee Stock Option Scheme, 2026, and the incorporation of a wholly owned subsidiary in Vietnam. Additionally, the company has approved the subscription of equity shares in Alivira Animal Health Limited, a wholly owned subsidiary, through a rights issue.
Viyash Scientific Limited
Viyash Scientific Limited has scheduled a conference call with its Analysts/Investors on August 12, 2026, to discuss its Q1FY27 earnings/financial results.
Viyash Scientific Limited
Viyash Scientific Limited has informed the Exchange about ESOP Allotment. The company has approved the allotment of 20,01,336 Equity Shares of Rs. 2/- each to eligible optionees at an exercise price of Rs. 86/- per equity share. The issued and paid-up equity share capital of the Company will increase from Rs. 87,37,50,954/- to Rs. 87,77,53,626 /-.